Stem Cell Therapy Outperforms DMTs for Highly Active RRMS.
Recent studies suggest that stem cell therapy may be most effective when given early in the disease course of multiple sclerosis (MS). Ocrevus has been found to limit brain volume loss in people with relapsing MS, while fenebrutinib has shown promise in reducing brain lesions in a Phase 2 clinical trial. Another experimental oral therapy, vidofludimus calcium, may reduce inflammation and protect neurons, potentially preventing neurodegeneration and disability accumulation for people with all forms of MS.